Shots:

• Glenmark has received the regulatory approval to commercialize the combination therapy of remogliflozin etabonate (100mg) + metformin hydrochloride (500/1000mg) as an adjunct to diet and exercise to improve glycemic control in T2D Mellitus patients in India under the brand names ‘Remo-M’ and Remozen-M’
• In Apr’2019- Glenmark has received approval of remogliflozin (100mg- bid) based on the P-III clinical study results evaluating remogliflozin vs dapagliflozin. With this approval- India became the first country to access remogliflozin with Glenmark being the first company to launch remogliflozin in India as ‘Remo’ and ‘Remozen’.
• Remogliflozin is a SGLT2 inhibitor- being studied in 26 global clinical studies and is launched in India as monothx. at a breakthrough price which is over 50% lower than the existing SGLT2 inhibitors available in India

Click here to­ read full press release/ article | Ref: Glenmark | Image: GMP News